U.S. FDA approves INVOKANA™ (canagliflozin) for the treatment of adults with Type 2 diabetes
29 March 2013 | By Janssen Pharmaceuticals
The U.S. FDA has approved INVOKANA™...
List view / Grid view
News
Sanofi to invest USD 75 million in a new manufacturing facility in Vietnam
29 March 2013 | By Sanofi
“This new production and development center is the largest investment ever made by Sanofi in Vietnam..."
Undergraduate studies enter a whole new world with Tecan’s Infinite® M200 PRO
28 March 2013 | By kdm communications
Tecan’s Infinite® M200 PRO multimode microplate readers are helping McMaster Uni...
Pfizer’s BOSULIF® (bosutinib) receives conditional marketing authorization from the European Commission
28 March 2013 | By Pfizer
“I’m delighted the EC has approved BOSULIF..."
EMA accepts MAA submission of Shionogi’s ospemifene for the treatment of VVA
27 March 2013 | By BusinessWire
Shionogi Limited announced that the EMA accepted its MAA submission for ospemifene...
Avacta’s Optim® 1000 helps de-risk preformulation studies
27 March 2013 | By kdm communications limited
Avacta Analytical has recently undertaken preformulation studies for a new targeted secretion inhibitor (TSI)...
Merck announces FDA acceptance of BLA for investigational grass pollen allergy immunotherapy tablet
27 March 2013 | By Merck
“We are pleased to have achieved this important milestone..."
Biogen Idec’s TECFIDERA™ approved in US as a first-line oral treatment for multiple sclerosis
27 March 2013 | By Biogen Idec
The U.S. FDA has approved TECFIDERA™...
Boehringer Ingelheim and Eli Lilly and Company announce acceptance of EMA application for investigational Type 2 Diabetes treatment empagliflozin*
26 March 2013 | By Ogilvy HealthPR London
“We are pleased with the promising results..."
Gilead announces update on Phase 3 study of oral fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients
26 March 2013 | By Gilead Sciences
Gilead Sciences provided an update on ION-1...
Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000
26 March 2013 | By Novartis
Latest global patient-use data...
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
26 March 2013 | By Boehringer Ingelheim
A new perspective from the U.S. FDA...
XELJANZ® approved in Japan for the treatment of adults with rheumatoid arthritis
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
25 March 2013 | By GlaxoSmithKline
GSK received a Complete Response letter...
Daiichi Sankyo receives approval in Japan for manufacture and marketing of PRALIA(R)
25 March 2013 | By Daiichi Sankyo
Approval to manufacture and market the osteoporosis treatment...
